Moleculin Biotech Updates on Pivotal Annamycin AML Trial with Positive Blinded Efficacy Data
MBRX sits 34% above its 52-week low of $1.79.
Summary
Moleculin Biotech released an investor presentation detailing preliminary positive blinded efficacy data from its Phase 3 Annamycin AML trial and confirmed unblinding for 45 subjects is expected by late Q2 2026.
Key Events · Product Development and Regulatory · MBRX
-
Preliminary Blinded Efficacy Data
The Phase 3 MIRACLE trial for Annamycin in relapsed/refractory AML shows preliminary blinded efficacy data of a 30% Complete Remission (CR) rate and a 40% Complete Remission with incomplete hematologic recovery (CRc) rate for 30 subjects. This data is highlighted as outperforming existing second-line AML therapies.
-
Upcoming Unblinding of Phase 3 Data
Unblinding of data for 45 subjects in the pivotal MIRACLE trial is on track to occur prior to the end of June 2026 (late Q2), which is a significant near-term catalyst for the company.
-
Financial Runway Confirmed
The company reiterated its pro forma cash on hand of approximately $11.1 million, providing a cash runway into Q3 2026. An At-The-Market (ATM) program with $7.2 million available remains in place.
Analysis · MBRX · Life Sciences
This 8-K provides an investor presentation with crucial updates on Moleculin Biotech's lead drug candidate, Annamycin, in its pivotal Phase 3 MIRACLE trial for relapsed/refractory AML. The disclosure of preliminary blinded efficacy data, showing a 30% Complete Remission (CR) rate and 40% Complete Remission with incomplete hematologic recovery (CRc) rate, is a significant positive signal for a clinical-stage biotech. This data is presented as superior to existing second-line AML therapies. The confirmation that unblinding for 45 subjects is on track for late Q2 2026 creates a near-term catalyst. While the company continues to face a 'going concern' warning and a short cash runway into Q3 2026, positive clinical progress is vital for investor confidence and future financing efforts.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $1.79 to $24.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.